AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
These glial cells biomarkers identified in liquid biopsy for AD detection and progression can be used for early and differential diagnosis of AD and other dementia conditions.
This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.
The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.
The review finds that the real worth of these biomarkers is not just in their availability but also in choosing the right biomarker to the right clinical question and in maintaining the integrity of the measurement chain between sample collection and interpreting the results.
This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.